Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes

Diabetes

Volumn 58, Issue 3, 2009, Pages 701-709

  Davis, Stephen N ^a,b   Mann, Stephanie ^a   Briscoe, Vanessa J ^a   Ertl, Andrew C ^a   Tate, Donna B ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b Veterans Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; FATTY ACID; GLUCOSE; GLYCEROL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LACTIC ACID DERIVATIVE;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEFENSE MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOTHESIS; INSULIN BLOOD LEVEL; INSULINEMIA; INTENSIVE CARE; MALE; METABOLIC REGULATION; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM; BLOOD; DRUG COMBINATION; HOMEOSTASIS; METABOLISM; NEUROSECRETION; PATHOPHYSIOLOGY;

AUTONOMIC NERVOUS SYSTEM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LACTATES; NEUROSECRETORY SYSTEMS;

EID: 62749102585     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db08-1230     Document Type: Article

References (34)

1. Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. U.K. Prospective Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS). Lancet 352:837-853, 1998
3. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 31:S3-S78, 2008
4. Diabetes Control and Complications Trial Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450 -459, 1991
5. Diabetes Control and Complications Trial (DCCT) Research Group: Hypo- glycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
6. Gabriely I, Shamoon H: Hypoglycemia in diabetes: common, often unrecognized. Cleveland Clin J Med 71:335-342, 2004
7. Briscoe VJ, Davis SN: Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology and management. Clinical Diabetes 24:115121, 2006
8. Briscoe VJ, Davis SN: Hypoglycemia in Type 1 Diabetes in Adults: Principles and Practice. Jabbour S, Stephens E, Hirsch I, Goldstein B, Garg S, Riddle M, Eds. New York, Taylor 7 Francis Informa, 2008
9. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S, HOPE Investigators: The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48: 1749-1755, 2005
10. Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008
11. ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572, 2008
12. Burge MR, Sobhy TA, Qualls CR, Schade DS: Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemic symptoms. J Clin Endocrinol Metabol 86:5471-5478, 2001
13. Levy CJ, Kinsley BT, Bajaj A, Simonson DC: Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 21:1330-1338, 1998
14. Korzon-Burakowska A, Hopkins D, Matyka K, Lomas J, Pernet A, Mac- donald I, Amiel S: Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 21:283-290, 1998
15. Spyer G, Hattersley AT, MacDonald IA, Amiel S, MacLeod KM: Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 365:1970-1974, 2000
16. Segel SA, Peramore DS, Cryer PE: Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51:724-733, 2002
17. Israelian Z, Szoke E, Woerle J, Bokhari S, Shorr M, Schwenke D, Cryer PE, Gerich J, Meyer C: Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 55:593-598, 2006
18. Abumrad NN, Rabin D, Diamond MC, Lacy WW: Use of a heated superficial hand vein as an alternative site for measurement of amino acid concentration and for the study of glucose and alanine kinetics in man. Metabolism 30:936-940, 1981
19. DeFronzo R, Tobin K, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E216-E223, 1979
20. Amiel SA, Tambolane WV, Simonson DC, Sherwin R: Defective glucose counterregulation after strict control of insulin-dependent diabetes mellitus. N Engl J Med 316:1376-1383, 1987
21. Wallin BG, Sundlof G, Eriksson BM, Dominiak P, Grobecker H, Lindblad LE: Plasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man. Acta Physiol Scand 111:69-73, 1981
22. Sandoval DA, Ertl AC, Richardson MA, Tate DB, Davis SN: Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes 52: 1749-1755, 2003
23. Wall JS, Steele R, Debodo RD, Altszuler N: Effect of insulin on utilization and production of circulating glucose. Am J Physiol 189:43-50, 1957
24. Aguilar-Parada E, Eisentraut AM, Unger RH: Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257:415-419, 1969
25. Wide L, Porath J: Radioimmunoassay of proteins with the uses of sephadex- coupled antibodies. Biochim Biophys Acta 130:257-260, 1966
26. Causon R, Caruthers M, Rodnight R: Assay of plasma catecholamines by liquid chromatography with electrochemical detection. Anal Biochem 116:223-226, 1982
27. 131I]-labeled human growth hormone of high specific activity. Nature 194:495-496, 1962
28. Hagopian W, Lever E, Cen D, Emmonoud D, Polonsky K, Pugh W, Moosa A, Jaspan J: Predominance of renal and absence of hepatic metabolism of pancreatic polypeptide in the dog. Am J Physiol 245:171-177, 1983
29. Lloyd B, Burrin J, Smythe P, Alberti KGMM: Enzymatic fluorometric continuous flow assays for blood glucose, lactate, pyruvate, alanine, glycerol and 2-hydroxybutyrate. Clin Chem 24:1724-1729, 1978
30. 63NI as tracer. Anal Biochem 26:105-113, 1970
31. Deary L, Hepburn D, Macleod K, Frier BM: Partitioning the symptoms of hypoglycemia using multi-sample confirmatory factor analysis. Diabetologia 36:771-770, 1993
32. Hawkins M, Gabriely L, Wozniak R, Reddy K, Rossetti L, Shamoon H: Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes 51:2179-2189, 2002
33. Donath MY, Schumann DM, Faulenback M, Ellingsgaard H, Perren A, Ehses JA: Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31:S161-S164, 2008
34. Davis MR, Mellman M, Shamoon H: Further defects in counterregulatory response induced by recurrent hypoglycemia in IDDM. Diabetes 41:1335-1340, 1992